Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice, Am J Psychiatry. janv, vol.163, issue.1, pp.28-40, 2006. ,
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression, N Engl J Med. 23 mars, vol.354, issue.12, pp.1231-1273, 2006. ,
Residual symptoms after partial remission: an important outcome in depression, Psychol Med. nov, vol.25, issue.6, pp.1171-80, 1995. ,
Relapse in Major Depressive Disorder: Analysis With the Life Table, Archives of General Psychiatry. 1 août, vol.39, issue.8, p.911, 1982. ,
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II, Clin Pharmacokinet, vol.48, issue.12, pp.761-804, 2009. ,
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry. mai, vol.9, issue.5, pp.442-73, 2004. ,
Clinical applications of CYP genotyping in psychiatry, J Neural Transm (Vienna). janv, vol.122, issue.1, pp.5-28, 2015. ,
Pharmacogenetics: from bench to byte--an update of guidelines, Clin Pharmacol Ther. mai, vol.89, issue.5, pp.662-73, 2011. ,
Drugs. Table of pharmacogenomic biomarkers in drug labeling, 2016. ,
Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation -recommendations from the French National Network of Pharmacogenetics, Therapie. avr, vol.72, issue.2, pp.311-319, 2017. ,
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants, Clin Pharmacol Ther. mai, vol.93, issue.5, pp.402-410, 2013. ,
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, Clinical Pharmacology & Therapeutics. août, vol.98, issue.2, pp.127-161, 2015. ,
Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility, Journal of Psychiatric Research. janv, vol.96, pp.100-107, 2018. ,
Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis, CNS Spectrums. août, vol.22, issue.04, pp.315-339, 2017. ,
Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry, vol.2, pp.172-172, 2012. ,
Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting: Pharmacogenetics and Genomics, vol.23, pp.535-583, 2013. ,
Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder, Biomarkers in Medicine. juin, vol.7, issue.3, pp.429-468, 2013. ,
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial, BMC Psychiatry. déc, vol.17, issue.1, 2017. ,
Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Current Medical Research and Opinion. 2 sept, vol.31, pp.1633-1676, 2015. ,
Do we need pharmacogenetics to personalize antidepressant therapy?, Cellular and Molecular Life Sciences. sept, vol.70, issue.18, pp.3327-3367, 2013. ,
Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies, Neuroscience Letters, 2018. ,
Pharmacogenomics of antidepressant drugs, Pharmacology & Therapeutics. oct, vol.124, issue.1, pp.57-73, 2009. ,
How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping, Pharmacogenomics, vol.15, issue.5, pp.655-665, 2014. ,
Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels, Pharmacogenomics. janv, vol.14, issue.2, pp.215-238, 2013. ,
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response, Ther Drug Monit. août, vol.30, issue.4, pp.474-82, 2008. ,
Paroxetine in major depression: correlating plasma concentrations and clinical response, Pharmacopsychiatry. mai, vol.37, issue.3, pp.123-129, 2004. ,
Escitalopram plasma levels and antidepressant response, European Neuropsychopharmacology. sept, vol.27, issue.9, pp.940-944, 2017. ,
Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients, J Psychopharmacol (Oxford). déc, vol.16, issue.4, pp.369-72, 2002. ,
Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression, J Clin Psychopharmacol. juin, vol.28, issue.3, pp.325-333, 2008. ,
Contribution of common genetic variants to antidepressant response, Biol Psychiatry. 1 avr, vol.73, issue.7, pp.679-82, 2013. ,
Socio-demographic and clinical predictors of non-response/nonremission in treatment resistant depressed patients: A systematic review, Psychiatry Research. juin, vol.240, pp.421-451, 2016. ,
Serotonin transporter gene polymorphisms and treatment-resistant depression, Prog Neuropsychopharmacol Biol Psychiatry. 16 août, vol.34, issue.6, pp.934-943, 2010. ,
Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression, Journal of Neural Transmission. août, vol.114, issue.8, pp.1065-1073, 2007. ,
Role of glutamate receptors and glial cells in the pathophysiology of treatmentresistant depression, Progress in Neuro-Psychopharmacology and Biological Psychiatry. oct, vol.70, pp.117-143, 2016. ,
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample, PLoS ONE. 2 avr, vol.3, issue.4, p.1872, 2008. ,
Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients, International Clinical Psychopharmacology. sept, vol.24, issue.5, pp.250-256, 2009. ,
Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression, Journal of Psychiatric Research, vol.38, issue.6, pp.577-82, 2004. ,
Treatment resistant depression: methodological overview and operational criteria, Eur. Neuropsychopharmacol, vol.9, pp.83-91, 1999. ,
Targeting treatment-resistant depression, J. Pharm. Pract, vol.24, pp.520-533, 2011. ,
Treatment-resistant depression: therapeutic trends, challenges, and future directions, Patient Prefer. Adherence, vol.6, pp.369-388, 2012. ,
Management of treatment-resistant depression, Psychiatr. Clin. N. Am, vol.35, pp.249-265, 2012. ,
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am. J. Psychiatry, vol.163, pp.1905-1917, 2006. ,
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression, Psychiatr. Serv, vol.60, pp.1439-1445, 2009. ,
Approaches to understanding and addressing treatment-resistant depression: a scoping review, Depress. Res. Treat, p.469680, 2012. ,
Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care, Prim. Care, vol.34, pp.505-519, 2007. ,
Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview, Ann. Med, vol.40, pp.149-159, 2008. ,
What is the meaning of treatment resistant/ refractory major depression (TRD)? A systematic review of current randomized trials, Eur. Neuropsychopharmacol, vol.17, pp.696-707, 2007. ,
Treatment-resistant depression: resistant to definition?, Acta.Psychiatr.Scand, vol.112, issue.4, pp.302-309, 2005. ,
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach, Journal of Affective Disorders. mars, vol.156, pp.1-7, 2014. ,
Achieving gains beyond response, 2000. ,
Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse, 1998. ,
What happens to patient with treatment-resistant depression?, J Of Affective Disorder, vol.116, pp.4-11, 2006. ,
The economic burden of depression in the United States: how did it change between 1990 and, J. Clin. Psychiatry, vol.64, pp.1465-1475, 2000. ,
Cost of depression among adults in England in 2000, Br. J. Psychiatry, vol.183, pp.514-519, 2003. ,
Risk factors for treatment resistance in unipolar depression: A systematic review, J. Of Affective Disorder, vol.171, pp.137-141, 2015. ,
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study, J. Clin. Psychiatry, vol.68, pp.1062-1070, 2007. ,
, Clinical Pharmacogenetics Implementation Consortium, CPIC Guidelines, 2014.
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial, BMC Psychiatry, vol.17, p.250, 2017. ,
, Declaration of Helsinki from the World Medical Association (WMA) -Ethical principles for medical research involving human subjects. 64th WMA General Assembly, 2013.
, International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, 1996.
A rating scale for depression, J Neurol Neurosurg Psychiatry. févr, vol.23, pp.56-62, 1960. ,
A new depression scale designed to be sensitive to change, The British Journal of Psychiatry. 1 avr, vol.134, issue.4, pp.382-391, 1979. ,
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update, Pharmacopsychiatry. sept, vol.44, issue.06, pp.195-235, 2011. ,
, Methods in Enzymology, pp.199-210, 1996.
Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, pp.703-714, 2002. ,
Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, pp.300-307, 2005. ,
, Pharmacogene Variation Consortium. Banque de données en pharmacogénétique
Relapse in Major Depressive Disorder: Analysis With the Life Table, Archives of General Psychiatry. 1 août, vol.39, issue.8, p.911, 1982. ,
Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis, PLoS ONE, vol.6, issue.12, p.28943, 2011. ,
, Clinical Pharmacogenetics Implementation Consortium (CPIC)
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther. janv, vol.79, issue.1, pp.103-116, 2006. ,
Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients, Pharmacogenomics J. oct, vol.11, issue.5, pp.359-67, 2011. ,
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy, J Thromb Haemost JTH. août, vol.8, issue.8, pp.1685-93, 2010. ,
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update, Clin Pharmacol Ther, 2016. ,
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update, Clin Pharmacol Ther. avr, vol.95, issue.4, pp.376-82, 2014. ,
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update, Clin Pharmacol Ther. sept, vol.94, issue.3, pp.317-340, 2013. ,
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.234-276, 2008. ,
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics. févr, vol.47, issue.1, pp.75-85, 2006. ,
Index for rating diagnostic tests, Cancer, vol.3, issue.1, pp.32-35, 1950. ,
Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distributions of levels of serum pepsinogen i, ii and of pg i/pg ii ratios in a gastric cancer case-control study, Journal of epidemiology, vol.7, issue.3, pp.143-151, 1997. ,
Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Preventive veterinary medicine, vol.45, pp.23-41, 2000. ,
Basic principles of roc analysis, Seminars in nuclear medicine, vol.8, pp.283-298, 1978. ,
Strategies for graphical threshold determination, Computer methods and Programs in Biomedicine, vol.35, issue.2, pp.141-150, 1991. ,
An Expanded View of Complex Traits: From Polygenic to Omnigenic, Cell, vol.169, pp.1177-1186, 2017. ,